Alexis Guédon: Cancer-Associated Upper-Extremity Deep Vein Thrombosis
Alexis Guédon, Junior Deputy Editor at the European Journal of Preventive Cardiology, shared on LinkedIn about a recent article he and his colleagues co-authored, published in JACC Journals, adding:
“Upper-extremity deep vein thrombosis in cancer is sometimes viewed primarily as a catheter-related complication with a relatively low risk of recurrence.
In JACC Journals: CardioOncology, we report findings from 5,195 patients enrolled in the international RIETE registry, including 2,210 with active cancer.
We found that:
- Cancer was associated with higher risks of recurrent venous thromboembolism and bleeding.
- Risk differed substantially by cancer site: lung cancer had the highest recurrence risk, whereas genitourinary cancers had the highest bleeding risk.
- After anticoagulation discontinuation, the 2-year recurrence risk reached 17.2% in patients with lung cancer.
- Longer anticoagulation was associated with a lower risk of recurrence after treatment discontinuation, although these observational association should not be interpreted as causal.
These results suggest that cancer-associated upper-extremity deep vein thrombosis is more than a mechanical catheter-related complication.
Tumor biology appears to influence the balance between thrombosis and bleeding, supporting careful reassessment before anticoagulation is discontinued.
A study led by Olivier Espitia and Manuel Monreal, with the RIETE Investigators.”
Title: Upper Extremity Deep Vein Thrombosis in Cancer Patients: Clinical Course by Cancer Site
Authors: Olivier Espitia, Alexis F. Guedon, Emma Courouve, Benjamin Brenner, Juan José López-Núñez, Romain Chopard, Alicia Lorenzo, Patricia Sigüenza, Son Truong Nguye
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 17, 2026, 17:47Anuoluwapo Oladunjoye: Every Blood Film Has a Story to Tell
-
Jun 17, 2026, 17:46Svetislav Matic: A Patient-Centric Interdisciplinary Approach to Perioperative Bleeding Management
-
Jun 17, 2026, 17:45Paul Breillat: New Insights Into the Role of RIPK1-Mediated Cell Death in VEXAS syndrome
-
Jun 17, 2026, 17:44Konstantin Yenkoyan: New Publication Alert – Autism and Iron Dysregulation
-
Jun 17, 2026, 17:44Ifeanyichukwu Ifechidere: Why Fibrinolysis Matters as Much as Clot Formation
-
Jun 17, 2026, 17:17Soma Agrawal: Transfusion Medicine in India – How Far We Have Come, and How Far We Must Go
-
Jun 17, 2026, 16:52Asayil Basalim: A Milestone in Medical Laboratory Science Training
-
Jun 17, 2026, 16:43Aleksandra Pikula: Canada’s First Women in Midlife Brain Health and Stroke Prevention Program Is Officially Launched
-
Jun 17, 2026, 16:42Alejandro González Veliz: Not Every Acs Patient Needs 12 Months of Dapt